KLRA Kailera Therapeutics, Inc.
Kailera Therapeutics, Inc. (KLRA) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
Where they traded
Last open-market purchase: April 20, 2026 .
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| 3 fills | Buy | 10,460,938 | $16.00 | $167.4M | 26,255,581 | ||
| Kaplan Andrew T. | Director | Buy | 8,398,438 | $16.00 | $134.4M | 26,255,581 | |
| Koppel Adam | Director | Buy | 1,562,500 | $16.00 | $25.0M | 22,583,268 |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.